Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukemia: a report from the Eastern Cooperative Oncology Group

The treatment of relapsed acute myeloid leukemia (AML) remains unsatisfactory. We conducted a phase II randomized trial where patients received intermediate-dose cytarabine for four days followed by gemtuzumab ozogamicin on day 5 (Arm A), or combined with liposomal daunorubicin for three days (Arm B...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Litzow, Mark R., Othus, Megan, Cripe, Larry D., Gore, Steven D., Lazarus, Hillard M., Lee, Sandra J., Bennett, John M., Paietta, Elisabeth M., Dewald, Gordon W., Rowe, Jacob M., Tallman, Martin S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2809127/
https://ncbi.nlm.nih.gov/pubmed/19804455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2009.07917.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados